Edition:
United Kingdom

Biogaia AB (BIOGb.ST)

BIOGb.ST on Stockholm Stock Exchange

290.00SEK
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
290.00kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,781
52-wk High
369.50kr
52-wk Low
278.50kr

Latest Key Developments (Source: Significant Developments)

Biogaia Q3 operating profit up 11 pct​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Biogaia AB :Biogaia says Q3 ‍net sales amounted to 147.7 million SEK(126.0), up 17 pct​.Says Q3 ‍operating profit was 53.6 million SEK (48.4), up 11 pct.CEO says "ongoing strengthening of the organization and the close collaboration with our partners are paying off and we are continuing to pursue our strategic initiatives."​.  Full Article

Biogaia Q4 adj. operating profit rises 45 pct, lifts margin target
Friday, 10 Feb 2017 

Biogaia AB : Q4 net sales amounted to SEK 138.8 million (104.4) . Q4 operating profit excluding IBT was SEK 46.4 million (32.0) . Says The long-term financial target is an operating margin (operating profit in relation to sales) of at least 34% (previously 30%) with continued strong growth and increased investments in research, product development, brand building and the sales organization . Says board proposes a dividend according to policy of SEK 3.16 (3.03) per share and an extraordinary dividend of SEK 4.34 (1.97) per share, amounting to a total dividend of SEK 7.50 (5.00) per share For the original story click here: http://bit.ly/2lxRkRt Further company coverage: [BIOGb.ST] (Stockholm Newsroom) ((stockholm.newsroom@thomsonreuters.com; +46 (0)8-700 10 10;)).  Full Article

Biogaia says Q2 net sales rose to SEK 136.0 mln
Wednesday, 17 Aug 2016 

Biogaia says: Q2 net sales amounted to SEK 136.0 million (134.0). . Q2 Net sales in Business Unit Paediatrics reached SEK 106.7 million (108.8). . Q2 operating profit excluding IBT was sek 53.4 million (48.4) and including IBT, operdating profit was SEK 53.4 million. . Profit after tax excluding IBT was SEK 38.6 million (40.4) .Second quarter earnings were driven by very strong sales in Europe where the Easy Dropper launch continues, strong sales in Asia and modest sales in the USA and Canada..  Full Article

Biogaia Q1 operating profit falls
Tuesday, 10 May 2016 

Biogaia Q1 : Operating profit was SEK 46.1 million (52.6) .Q1 net sales amounted to SEK 133.9 million (138.8).  Full Article

BioGaia says oral health probiotics to be launched in Hong Kong
Monday, 25 Apr 2016 

BioGaia AB:Has signed an agreement with BioWellTech Co Ltd for the rights to sell BioGaia ProDentis in Hong Kong.The launch is planned to take place during Q3.  Full Article

BioGaia AB says analysis confirms effectiveness of BioGaia ProDentis in periodontitis
Friday, 18 Mar 2016 

BioGaia AB:Says meta-analysis confirms effectiveness of Biogaia prodentis in periodontitis.  Full Article

BioGaia to distribute and list IBT subsidiary
Friday, 12 Feb 2016 

BioGaia AB:Says ‍proposes distribution and separate listing of Infant Bacterial Therapeutics (IBT) subsidiary.To finance IBT's first clinical trial, company has capital need of around 100 mln Swedish crown.Capital need planned to be raised through a rights issue in Q2 with preferential rights for IBT's shareholders.March 29 set to be first day of trading in IBT's shares on Nasdaq First North​.  Full Article

BioGaia plans to distribute total dividend of SEK 5.00 per share​
Friday, 12 Feb 2016 

BioGaia AB:Says ‍board proposes dividend of 3.03 Swedish crowns per share to be paid for 2015.Additionally, proposes extraordinary dividend of 1.97 crowns per share.Plans to distribute total oftotal dividend of SEK 5.00 per share.​.  Full Article

BioGaia AB subsidiary closer to FDA approval for clinical studies
Friday, 8 Jan 2016 

BioGaia AB:Says subsidiary IBT has U.S. IND open and Swedish CTA approved for clinical study.Infant Bacterial Therapeutics (IBT), a subsidiary of BioGaia, announced that the IND (Investigational New Drug) for the prevention of necrotizing enterocolitis (NEC), has been accepted by FDA (the U.S. Food and Drug Administration).Furthermore, IBT has received approval from the MPA (Medical Product Agency) to conduct its clinical trial in Sweden.IBT has an open IND accepted by the FDA, which is an important step in allowing IBT to start clinical studies in the U.S.  Full Article

BRIEF-Biogaia Q3 operating profit up 11 pct​

* Biogaia says Q3 ‍net sales amounted to 147.7 million SEK(126.0), up 17 pct​